8-K: Iridex Reports Positive Adjusted EBITDA in Q4 2024, Secures $10 Million Strategic Investment

Iridex Corporation announces positive adjusted EBITDA for the fourth quarter of 2024 and a strategic investment of $10 million, signaling improved financial health.

Summary

• Iridex Corporation reported its financial results for the fourth quarter and full year ended December 28, 2024.
• The company achieved positive adjusted EBITDA in Q4 2024.
• Operating expenses decreased by 24% to $6.1 million in Q4 2024, compared to $8.0 million in the prior year period, due to a cost reduction program.
• Total revenue for Q4 2024 was $12.7 million, slightly up from $12.5 million in the prior year quarter.
• Cyclo G6 product family revenue reached $3.3 million in Q4 2024, compared to $3.0 million in the prior year quarter.
• The company sold 13,300 Cyclo G6 probes and 47 Cyclo G6 Glaucoma Laser Systems in Q4 2024.
• Retina product revenue was $7.3 million in Q4 2024, compared to $7.5 million in the prior year quarter.
• Net loss for Q4 2024 was $0.8 million, an improvement from $3.0 million in the prior year quarter.
• Iridex strengthened its balance sheet with a $10 million strategic investment announced on March 19, 2025.
• Full year 2024 revenue was $48.7 million, compared to $51.9 million in 2023.
• Cyclo G6 glaucoma product family revenue for 2024 was $12.7 million, compared to $13.4 million in 2023.
• The company sold 55,400 Cyclo G6 probes and 125 Cyclo G6 Glaucoma Laser Systems in 2024.
• Retina product revenue for 2024 was $27.8 million, compared to $29.4 million in 2023.
• Operating expenses for 2024 decreased to $27.8 million, compared to $31.8 million in 2023.
• Net loss for 2024 was $8.9 million, compared to $9.6 million in the prior year.
• Cash and cash equivalents as of December 28, 2024, were $2.4 million, not including the $10 million strategic investment.
• The company expects to achieve cash flow breakeven and positive adjusted EBITDA in 2025 with revenue consistent with 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the achievement of positive adjusted EBITDA in Q4, the strategic investment, and the cost reduction program. However, the decrease in full-year revenue and cash balance tempers the overall optimism.

Positives

• Positive adjusted EBITDA in Q4 2024 indicates improved operational efficiency.
• Successful implementation of cost reduction program led to significant decrease in operating expenses.
• Strategic investment of $10 million strengthens the balance sheet and provides capital for growth initiatives.
• Net loss decreased in both Q4 2024 and full year 2024, showing progress towards profitability.
• Increased physician engagement following the November 2024 Local Coverage Determination (LCD) is expected to improve bottom line results.
• Gross profit for the fourth quarter of 2024 was $5.6 million or a 44.0% gross margin, an increase compared to $4.9 million, or a 39.2% gross margin, in the same period of the prior year driven by geographic and product mix.

Negatives

• Full year 2024 revenue decreased to $48.7 million from $51.9 million in 2023.
• Cash and cash equivalents were $2.4 million as of December 28, 2024, a reduction of $1.5 million in the quarter.
• Retina product revenue decreased by 6% for the full year 2024.
• Cyclo G6 glaucoma product family revenue decreased for the full year 2024 due to reimbursement uncertainty in the U.S.

Risks

• Reimbursement uncertainty in the U.S. could continue to impact glaucoma product sales.
• Deferral of capital purchases in the retina business could lead to lower system sales internationally.
• The company's ability to achieve cash flow breakeven and positive adjusted EBITDA in 2025 depends on maintaining revenue levels and cost discipline.
• The company's safe harbor statement mentions that actual results may differ materially from those described in forward-looking statements as a result of a number of factors.

Future Outlook

The company expects to achieve cash flow breakeven and positive adjusted EBITDA in 2025 on revenue generation consistent with 2024.

Management Comments

• Patrick Mercer, Iridex's President and CEO, stated that the company successfully executed the cost reduction program and achieved positive adjusted EBITDA operations in the fourth quarter.
• Mr. Mercer expects the company to deliver positive cash flow for the year on revenue in-line with that seen in the prior year.
• Mr. Mercer noted positive momentum in the business, including rising physician engagement following the November 2024 Local Coverage Determination (LCD).
• Scott Shuda, Iridexs Chairman of the Board of Directors, commented that the strategic investment in Iridex by Novel Innovations is an important development in the ongoing industry consolidation process.
• The Board of Directors will consider all opportunities deemed likely to benefit the Company's shareholders, including small accretive transactions, partnerships, and distribution agreements involving new product offerings.

Industry Context

The announcement mentions industry consolidation and potential deals involving the company's industry peers, suggesting a dynamic environment where strategic investments and partnerships are becoming increasingly important. Scott Shuda, Iridexs Chairman of the Board of Directors, commented that the strategic investment in Iridex by Novel Innovations is an important development in the ongoing industry consolidation process.

Comparison to Industry Standards

• It is difficult to compare Iridex's results directly to industry standards without knowing the specific performance metrics of its direct competitors.
• However, companies like Lumenis, Ellex (acquired by Nova Eye Medical), and Topcon offer similar products in the ophthalmology market.
• Comparing Iridex's revenue growth, profitability, and market share to these companies would provide a better understanding of its performance relative to industry benchmarks.
• The strategic investment by Novel Innovations could be compared to similar investments or acquisitions in the medical device industry to assess its value and impact.

Stakeholder Impact

• Shareholders will benefit from the strategic investment and potential for improved financial performance.
• Employees may experience job security due to the company's improved financial position.
• Customers can expect continued product development and support.
• Suppliers may see stable or increased demand for their products and services.
• Creditors may have increased confidence in the company's ability to meet its obligations.

Next Steps

• The company plans to schedule a special call for Iridex investors in April 2025 to discuss opportunities to expand its historic business via new products.
• The company intends to preannounce its first quarter 2025 results in April 2025.
• The Company will host a special call to be scheduled in mid-April 2025 to discuss the partnership with Novel Innovations.

Key Dates

Keywords

Iridex, financial results, EBITDA, revenue, glaucoma, retina, laser systems, medical devices, investment, cost reduction